• PDF: Delivered by email usually within 48 UK business hours.

Astellas Pharma Inc. (4503) - Pharmaceuticals & Healthcare
Deals and Alliances Profile

  • Publication Date:March 2011
  • Publisher:GlobalData
  • Product Type: Report
  • Pages:206

Astellas Pharma Inc. (4503) - Pharmaceuticals & Healthcare Deals and Alliances Profile

Astellas Pharma Inc. (4503) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Astellas Pharma Inc. (Astellas) is a global pharmaceutical company engaged in developing, manufacturing, marketing of pharmaceuticals and related products. The company's principal business activity is manufacturing, marketing and import/export of pharmaceuticals. Astellas's product portfolio is targeted against a wide range of diseases such as, immunology, infection, gastroenterology, oncology, immunology, pain, and diabetes among others. Additionally, Astellas has a broad pipeline of products under various stages of development such as phase I, II, II, and clinical and pre-clinical trials. It is focused on developing new drugs and supplying them to the patients in need. The company has vast research and development capabilities and efficient in-house sales force. Apart from Japan, Astellas supplies its products to global markets, including Ireland, the UK, Netherlands, China, Hong Kong, Thailand, Indonesia, and Philippines, among others. Astellas is headquartered in Chuo-Ku, Tokyo, Japan.

Astellas Pharma Inc. (4503) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you an in-depth data and trend analysis of the company's mergers and acquisitions (M&A) and financings. The report provides detailed information on M&A, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions registered by the company over a five year period. The report portrays detailed comparative data on the number of deals and their value subdivided by deal types, markets, and regions, besides highlighting the company's major recent financial deals.

Data presented in this report was derived from GlobalData's proprietary in-house Pharmaceuticals and Healthcare eTrack deals database and primary and secondary research.

Scope

  • Financial Deals - Analysis of the company's financial deals including M&A, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
  • Deals by Year - Chart and table displaying information on the number of deals and value reported by the company by year, for a five year period.
  • Deals by Type - Chart and table depicting information on the number of deals and value reported by the company by type such as M&A, Equity/Debt Offering etc.
  • Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region for North America, Europe, the Middle East and Africa and South and Central America.
  • Deals by Market - Chart and table showing information on the number of deals and value reported by the company, by market.
  • Major Recent Deals - Information on the company's major recent financial deals. Each such deal has a brief summary, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
  • Business Description - A brief description of the company's operations.
  • Key Employees - A list of the key executives of the company.
  • Important Locations and Subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key Competitors - A list of key competitors of the company.
  • Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements.

  • The profile analyzes the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divesture strategy

  • Deals are presented from the company's core business segments' perspective to help you understand its corporate strategy

Access detailed information about the company's recent financial deals that enables you to understand the key deals which have shaped the company

  • Major recent deals are presented in detail, which provides information on each deal's brief summary, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company to identify potential customers and suppliers.

  • The profile analyzes the company's business structure, locations and subsidiaries, key executives and their biographies and key competitors.

Stay up to date on the major developments affecting the company

  • Recent developments in the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research.

  • Key elements such as break up of deals by categories and information on detailed major deals are incorporated in the profile to assist your academic or business research needs.
  • Astellas Pharma Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
    • Astellas Pharma Inc., Pharmaceuticals & Healthcare Deals By Type, 2005 to YTD 2011
    • Astellas Pharma Inc., Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2011
    • Astellas Pharma Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2005 to YTD 2011
    • Astellas Pharma Inc., Pharmaceuticals & Healthcare, Medical Devices Deals, 2005 to YTD 2011
    • Astellas Pharma Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Astellas Pharma Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Astellas Pharma Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Astellas Pharma Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Astellas Pharma Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Astellas Pharma Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Astellas Pharma Inc., Pharmaceuticals & Healthcare, Deals Summary, 2005 to YTD 2011
    • Astellas Pharma Inc., Pharmaceuticals & Healthcare, Deal Details
    • Asset Purchase
    • MediGene Completes Sale Of European Rights For Eligard To Astellas
    • Astellas Pharma To Acquire Assets And Rights Of Diannexin From Pharmaceutical Product
    • Astellas Pharma Acquires AMEVIVE Rights And Assets From Biogen Idec
    • Astellas Pharma Acquires Research Facility From Dynogen Dynogen Pharmaceuticals
    • Venture Financing
    • EpiTherapeutics Secures An Additional $1.69 Million In Seed Financing
    • PhaseBio Pharmaceuticals Secures $15 Million In The Second Tranche Of Series B Financing Round
    • EpiTherapeutics Secures An Additional $1.37 Million In Seed Financing
    • Prolysis Secures $10 Million In Venture Financing
    • Partnerships
    • Cell Signaling Technology Enters Into Co-Marketing Agreement With Astellas Pharma
    • Maruho Enters Into Co-Marketing Agreement With Astellas
    • Astellas Pharma Enters Into Drug Discovery Collaboration With NITE
    • Astellas Pharma Enters Into An Agreement With Sanofi-Aventis
    • Astellas Pharma Enters Into Co-Development Agreement With UMN Pharma
    • Astellas Pharma Enters Into Co-Marketing Agreement With Bayer Schering Pharma
    • Astellas Pharma Extends Co-Promotion Agreement With Nippon Boehringer Ingelheim
    • Astellas Pharma Enters Into Co-Promotion Agreement With Sam Chun Dang
    • OM PHARMA Enters Into Co-Marketing Agreement With Astellas Pharma
    • Ambit Biosciences Enters Into Co-Development Agreement With Astellas Pharma
    • Medivation Enters Into Co-Development Agreement With Astellas Pharma
    • Simcere Pharmaceutical Enters Into Co-Development And Marketing Agreement With OSI Pharmaceuticals
    • Maxygen Forms Joint Venture With Astellas Pharma
    • Pfizer Enter Into Co-Promotion Agreement With Astellas Pharma
    • Astellas Pharma Enters Into Co-Promotion Agreement With AstraZeneca
    • Astellas Pharma Enters Into Co-Marketing Agreement With Zogenix
    • REGiMMUNE Enters Into Co-Development Agreement With Astellas Pharma
    • OSI Pharmaceuticals Expands Research Collaboration With AVEO Pharmaceuticals
    • Dako Denmark Enters Into An Agreement With OSI Pharmaceuticals
    • Astellas Pharma Enters Into Agreement With Maxygen
    • Astellas Pharma Enters Into Collaboration Agreement With CoMentis
    • BioTrove Enters Co-Marketing Agreement With OSI Pharmaceuticals
    • Proteros Expands Agreement With OSI Pharmaceuticals
    • Zeria Pharmaceutical Enters Into Agreement With Astellas Pharma
    • Abbott Laboratories Enters Into Agreement With Genentech, OSI And Roche
    • Effector Cell Institute Enters Into Co-Development Agreement With Astellas Pharma
    • OSI Pharmaceutical Enters Into Research Agreement With AVEO Pharmaceutical
    • Astellas Pharma Enters Into Co-Development Agreement With Kyoto University
    • Cardiome Pharma Amends Its Co-Development Agreement With Astellas US
    • AtheroGenics Extends Its Agreement With Astellas Pharma
    • Astellas Pharma Enters Into Co-Promotion Agreement With Sanofi-Aventis
    • Astellas Pharma Enters Into Collaboration Agreement With Chugai Pharmaceutical And National Institute of Technology and Evaluation
    • Portola Pharmaceuticals Enters Into Co-Development Agreement With Astellas Pharma
    • Metabolex Extends Research Agreement With Astellas Pharma
    • Licensing Agreements
    • Aestus Therapeutics Enters Into Licensing Agreement With Astellas Pharma
    • Hikma Pharmaceuticals Enters Into Licensing Agreement With Astellas Pharma
    • Oncolys BioPharma Enters Into Licensing Agreement With Astellas Pharma
    • Astellas Pharma Extends Collaboration With MorphoSys
    • OSI Pharmaceuticals Enters Into A Licensing Agreement With Ophthotech
    • SymBio Pharmaceuticals Enters Into Licensing Agreement With Astellas Pharma
    • MorphoSys Enters Into Licensing Agreement With Astellas Pharma
    • Ingenuity Systems Enters Into Licensing Agreement With Astellas Pharma
    • Mundipharma Enters Into License Agreement With Astellas Deutschland
    • Astellas Pharma Enters Into Licensing Agreement With FibroGen
    • Astellas Pharma Enters Into Licensing Agreement With Ilypsa
    • SymBio Pharmaceuticals Enters Into Licensing Agreement With Astellas Pharma
    • Apoxis Enters Into Licensing Agreement With Astellas Pharma
    • Astellas Pharma Enters Into Licensing Agreement With AVEO Pharmaceuticals For Tivozanib
    • Optimer Pharmaceuticals Enters Into Licensing Agreement With Astellas Pharma Europe For Fidaxomicin
    • Astellas Pharma Europe Expands Its Licensing Agreement With TOLMAR For Eligard
    • PanOptica Enters Into Licensing Agreement With OSI Pharmaceuticals
    • Astellas Pharma Extends Licensing Agreement With AstraZeneca
    • OSI Pharmaceuticals Enters Into Licensing Agreement With AVEO Pharmaceuticals
    • Astellas Pharma Enters Into Licensing Agreement With ASKA Pharmaceutical For AKP-002
    • Astellas Pharma Extends Licensing Agreement With Regeneron Pharmaceuticals
    • Teijin Pharma Enters Into An Agreement With Astellas Pharma
    • Basilea Pharmaceutica Enters Into Licensing, Co-Development And Co-Promotion Agreement with Astellas Pharma
    • Ironwood Pharmaceuticals Enters Into Licensing Agreement With Astellas Pharma
    • NeurogesX Enters Into Licensing Agreement With Astellas Pharma Europe
    • Teijin Pharma Enters Into Licensing Agreement With Astellas Pharma Taiwan
    • Millipore Enters Into Licensing Agreement With Astellas
    • MorphoSys Enters Into Licensing Agreement With Astellas
    • GlaxoSmithKline Pharmaceuticals Enters Into Licensing Agreement With Astellas Pharma
    • OSI Pharmaceuticals Enters Into Licensing Agreement For TGF ß3
    • OncoVista Innovative Therapies Enters Into Licensing Agreement With OSI Pharmaceuticals
    • OSI Pharmaceuticals Amends Licensing Agreement With Pfizer
    • Astellas Pharma Enters Into Licensing Agreement With Regeneron Pharmaceuticals
    • Astellas Enters Into License Agreement With Kirin Brewery Company
    • Theravance Extends Licensing Agreement With Astellas
    • CV Therapeutics Amends Licensing Agreement With Astellas US
    • Sanofi-Aventis Enters Into Licensing Agreement With Astellas Pharma
    • Astellas Pharma Enters Into Licensing Agreement With Toyama Chemical
    • Astellas Pharma Enters Into Licensing Agreement With Immuno-Bioogical Laboratories
    • Ferring Pharmaceuticals Enters Into Licensing Agreement With Astellas Pharma
    • PR Pharmaceuticals Enters Into Licensing Agreement With OSI Pharmaceuticals
    • Astellas Pharma Enters Into Licensing Agreement With XenoPort
    • Astellas Pharma Enters Into Licensing Agreement With Theravance
    • OSI Pharmaceuticals Enters Into Licensing Agreement With Merck
    • Fujisawa Pharmaceutical Enters Into Licensing Agreement With Carlsson Research
    • Equity Offering
    • Cytori Therapeutics Announces Private Placement Of $10 Million
    • Silence Therapeutics Completes Private Placement Of $24 Million
    • AVEO Pharmaceuticals Completes Private Placement Of $15 Million
    • AVEO Pharmaceuticals Completes Private Placement Of $5.5 Million
    • Divestiture - Company
    • Astellas Pharma Sells Hoshienu Pharma To Choseido Pharmaceutical
    • Daiichi Sankyo Acquires Zepharma From Astellas Pharma
    • Divestiture - Assets
    • Biota Holdings Acquires Antibacterial Assets From Prolysis
    • APP Pharmaceuticals Acquires Manufacturing Plant From Astellas Phama
    • Temmler Pharma Acquires Three European Plants From Astellas Pharma
    • QLT Acquires Full Rights To Aczone From Astellas
    • Debt Offering
    • OSI Pharmaceuticals Completes Private Placement Of Notes For $200 Million
    • OSI Pharmaceuticals Completes Senior Subordinated Notes Offering For $115 Million
    • Acquisition
    • Astellas Pharma To Acquire 83.3% Equity Interest In Perseid Therapeutics From Maxygen
    • Astellas Pharma Acquires OSI Pharmaceuticals
    • Astellas Acquires Agensys
    • Daiichi Sankyo Acquires Zepharma From Astellas Pharma
    • OSI Pharmaceuticals Acquires Eyetech Pharmaceuticals
    • OSI Pharmaceuticals Acquires Remaining Stake In Prosidion
    • Key Competitors
    • Key Employees
    • Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
    • Recent Developments
    • Strategy And Business Planning
    • Nov 10, 2009: Ironwood Enter Into Licencing Agreement With Astellas For Linaclotide
    • Nov 10, 2009: Ironwood, Astellas Enter Into Licensing Agreement For Linaclotide
    • Oct 27, 2009: Astellas, Medivation Enter Into Worldwide Agreement
    • Sep 25, 2009: Astellas Announces Extension Of Market In US For FLOMAX Capsules
    • Aug 26, 2009: Pfizer Signs Co-promotion Agreement For Caduet Combination Tablets With Astellas
    • Aug 04, 2009: AstraZeneca, Astellas Sign Co-promotion Agreement
    • Aug 03, 2009: Zogenix Signs Co-Promotion Agreement With Astellas For Sumavel DosePro
    • Jul 20, 2009: Astellas Establishes Affiliate In Brazil
    • Oct 01, 2008: Astellas Dissolves Its European Subsidiary Fujisawa Ireland
    • Corporate Communications
    • Mar 14, 2011: Astellas To Donate JPY100m For Earthquake Relief Efforts In Japan
    • Nov 02, 2010: Astellas Announces Senior Management Changes
    • Jul 02, 2010: Astellas Nominates President Of OSI Pharmaceuticals
    • Apr 19, 2010: Astellas To Support Relief Efforts Following Haiti Earthquake
    • Mar 19, 2010: Astellas Announces Changes To Director Nominees For Election To OSI's Board Of Directors
    • Mar 01, 2010: Astellas To Send Additional Relief Effort Following Haiti Earthquake
    • Mar 06, 2009: Astellas To Nominate Two Directors And Submit Proposal To Remove Remaining Four Directors Of Cv Therapeutics
    • Jun 01, 2006: Astellas Launches "vesicare®" For The Treatment Of Overactive Bladder In Japan
    • Legal and Regulatory
    • Mar 16, 2011: OSI, Genentech, Pfizer And Teva Reach Settlement Agreement In Tarceva Patent Case
    • Jan 10, 2011: Astellas To Review Strategic Business Alternatives For Prosidion Subsidiary
    • Oct 28, 2010: Astellas Pharma Files Patent Infringement Lawsuit Against Nycomed
    • Jun 28, 2010: Astellas And Teva Reach Agreement On VESIcare Patent Case
    • Oct 07, 2009: Astellas And Boehringer Ingelheim Reach Settlement With Impax On FLOMAX Patent Case
    • Feb 27, 2009: Astellas Files Lawsuit Against CV Therapeutics
    • Jul 22, 2008: Astellas And Boehringer Feled Lawsuit Against Flomax® Generic For Patient Infringement In The Us
    • Jul 22, 2008: Astellas And Boehringer Feled Lawsuit Against Flomax® Generic For Patient Infringement In The Us
    • Sep 10, 2007: Court Dismiss Appeal Filed By Taiyo Yakuhin, Co., Ltd Of Patent Infringementsuit On Oral Cephalosporin Antibiotic Cefzon® Capsule
    • Aug 09, 2007: Astellas Filed Lawsuit Against Taiyo Yakuhin Co., Ltd Claiming Damages On The Oral Cephalosporin Antibiotic Cefzon®
    • Feb 23, 2007: Astellas And Boehringer Won The Lawsuit Against Flomax® Generic For Patent Infringement In The Usa
    • Oct 23, 2006: Astellas, Tokyo Pharmar, And Aska Pharmaceutical Compromised For Infringement Of Patent On Harnal® Capsule
    • Nov 29, 2005: Astellas Sues Toyo Pharmar And Aska Pharmaceutical For Infringement Of Patent On Harnal Capsule
    • Sep 15, 2005: Astellas Filed Lawsuit Against Taiyo Yakuhin Co., Ltd. For Infringement Of Patent On The Oral Cephalosporin Antibiotic Cefzon Capsule
    • May 26, 2005: Astellas And King File Lawsuit Against Adenoscan® Generic For Patent Infringment In The Usa
    • May 16, 2005: Astellas And Boehringer Filed Lawsuit Against Flomax® Generic For Patent Infringement In The Usa
    • Government and Public Interest
    • Oct 28, 2009: Astellas Submits MAA To EMEA For Telavancin
    • Oct 16, 2009: MHLW Approves Symbicort Turbuhaler
    • Oct 07, 2009: Astellas, Boehringer Ingelheim Reach Settlement With Impax
    • Sep 11, 2009: Theravance, Astellas Report FDA Approval Of Vibativ
    • Aug 13, 2009: Astellas Provides Update On Complaint Challenging FDA's Decision On Citizen Petition
    • Aug 12, 2009: Astellas Provides Update On FDA's Decision On Citizen Petition
    • Product News
    • Dec 26, 2006: Astellas Pharma Us, Inc. Submits Supplemental New Drug Application For Antifungal Product Mycamine
    • Dec 26, 2005: Nda For Immunosuppressant Fk506 Modified Release Formulation Submitted In The Us
    • Dec 18, 2007: Announcement Of The Launch Of The Pulmonary Arterial Hypertension Agent Careload La Tablets 60ug In Japan
    • Nov 30, 2006: Snda For A Fast-Acting Postprandial Hypoglycemic Agent Fastic Tablet / Starsis Tablet For Combination Therapy With Insulin Sensitizer Was Filed
    • Nov 26, 2009: Pfizer, Astellas Launch Caduet Combination Tablets In Japan
    • Nov 20, 2008: Astellas Announces The Outcome Of Fdas Advisory Committee In The Us For Telavancin
    • Nov 14, 2007: Snda For A Fast-Acting Postprandial Hypoglicemic Agent Fastic Tablet / Starsis Tablet For Combination Therapy With Biguanide Was Approved
    • Nov 07, 2005: Theravance And Astellas To Collaborate On Telavancin, Investigational Antibiotic For Serious Infections
    • Nov 05, 2009: Theravance, Astellas Launch Vibativ In US
    • Oct 27, 2008: Astellas Launches The Immunosuppressant Graceptor In Japan
    • Oct 24, 2008: Astellas Announces The Withdrawal Of Eu Maa For Telavancin For Complicated Skin And Soft Tissue Infections
    • Oct 22, 2009: Zogenix, Astellas Report Positive Clinical Results For New Needle-free Delivery System
    • Oct 22, 2007: Theravance Receives Fda Approvable Letter For Telavancin For The Treatment Of Complicated Skin And Skin Structure Infections
    • Oct 22, 2007: Adenoscan Patent Lawsuits Settled
    • Oct 22, 2007: Announcement Of The Acquisition Of Marketing Approval For The Pulmonary Arterial Hypertension Agent Careload La Tablets 60ug In Japan
    • Oct 06, 2008: Astellas Launches Irribow For The Treatment Of Irritable Bowel Syndrome
    • Oct 04, 2007: Announcement Of The Launch Of Geninax Tablet, An Oral New-Type Quinolone Antibaterial Agent, In Japan
    • Sep 25, 2009: Astellas Announces Extension Of Market Exclusivity In The Us For Flomax Capsules
    • Sep 24, 2009: Astellas Filed Lawsuit Against Vesicare Genericfor Patent Infringement In The Us
    • Sep 19, 2007: Astellas Submitted A Response To The Fda Action Letter For Fk506 Modified Release Formulation For Kidney Transplantation
    • Sep 03, 2007: Astellas Announces The Extension Of Us Regulatory Review For The Snda Of Mycamine
    • Aug 11, 2008: Cardiom And Astellas Announce Receipt Of Fda Approvable Letter For Kynapid
    • Jul 10, 2009: Gaster Shows Effectiveness In Prevention Of Peptic Ulcers
    • Jul 10, 2006: Application Field For The Osteoporosis Treatment Ono-5920/Ym529 In Japan
    • Jul 07, 2009: Astellas Receives Approval For Prograf In Japan
    • Jul 03, 2006: Application For Approval Of Additional Indication For Type 2 Diabetic Nephropathy For "micardis", Angiotensin Ii Receptor Blocker, Is Filed
    • Jul 01, 2009: Astellas Announces Submission Of Pediatric Data For Flomax Capsules In The Us
    • Jun 24, 2008: New Strengh Added To Fluvoxamine Meleate, 75mg Tablets Launched
    • Jun 18, 2007: Astellas Announces The Launch Of Advagraf In The Uk And Germany
    • Jun 11, 2007: Announcement Of The Launch Of The Selective Cox-2 Inhibitor Celerox Tabletes In Japan
    • May 28, 2009: Astellas Receives FDA Approval For Prograf
    • May 26, 2009: Astella To Launch Protopic Ointment In Europe
    • May 13, 2005: Anti-Fungal Agent Mycaminetm Available To Physicians
    • May 07, 2007: Adverse Event Of Fg-2216 For The Treatment Of Anemia
    • May 01, 2007: Astellas And Theravance Announce Submission Of Telavancin Maa For The Treatment Of Complicated And Soft Tissue Infections In Europe
    • Apr 27, 2007: Astellas Receives An European Commission Approval For Advagraf
    • Apr 24, 2006: Closure Of Astellas Cns Research In Edinburgh
    • Apr 13, 2006: Maa Submission For Candin Antifungal Agent Micafungin In Eu
    • Apr 11, 2005: Prograf Is Approved For Additional Indication Of Rheumatoid Arthritis
    • Mar 20, 2007: Astellas Receives An Fda Action Letter For Prograf Snda
    • Mar 02, 2009: Astellas And Xenoport Announce Positive Results From Phase 2 Trial Of Asp8825/Xp13512 In Japan For Restless Legs Syndrome
    • Mar 02, 2007: Fda Approves Astellas' Vaprisol For The Treatment Of Hypervolemic Hyponatremia
    • Feb 26, 2007: Astellas Receives A Positive Chmp Opinion For Eu Marketing Authorisations For Fk506 Modified Release As A Once-Daily Immunosuppressant In Organ Transplantation
    • Feb 15, 2011: Astellas Withdraws Application For Marketing Approval Of Darexaban In Japan
    • Jan 27, 2006: Snda For A Fast-Acting Postprandial Hypoglicemic Agent Fastic Tablet / Starsis Tablet For Combination Therapy With Biguanide Was Filed
    • Jan 26, 2007: Approval For Candin Antifungal Agent Funguard For Prophylaxis Of Aspergillus And Candila Infections In Patients Undergoing Hsct And Immunosuppressant Prograf For Lupus Nephritis In Japan
    • Jan 23, 2007: Astellas Receives An Action Letter From Fda For Nda Of Fk506 Mr In The U.S
    • Jan 21, 2009: Approval For The Osteoprosis Treatment, Recalbon Tablets / Bonoteo Tablets
    • Jan 04, 2006: Fda Approves Astellas' Vaprisol For The Treatment Of Euvolemic Hyponatremia
  • Appendix
    • Methodology
    • About GlobalData
    • Contact Us
    • Disclaimer 206
  • List of Tables
    • Astellas Pharma Inc., Pharmaceuticals & Healthcare, Key Facts, 2010
    • Astellas Pharma Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
    • Astellas Pharma Inc., Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2011
    • Astellas Pharma Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2005 to YTD 2011
    • Astellas Pharma Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
    • Astellas Pharma Inc., Pharmaceuticals & Healthcare Deals By Type, 2005 to YTD 2011
    • Astellas Pharma Inc., Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2011
    • Astellas Pharma Inc., Deals By Therapy Area, 2005 to YTD 2011
    • Astellas Pharma Inc., Medical Devices Deals, 2005 to YTD 2011
    • Astellas Pharma Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Astellas Pharma Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Astellas Pharma Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Astellas Pharma Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Therapy Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Astellas Pharma Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Astellas Pharma Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Astellas Pharma Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Astellas Pharma Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Astellas Pharma Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Astellas Pharma Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Astellas Pharma Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Astellas Pharma Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Astellas Pharma Inc., Pharmaceuticals & Healthcare, Deals Summary, 2005 to YTD 2011
    • MediGene Completes Sale Of European Rights For Eligard To Astellas
    • Astellas Pharma To Acquire Assets And Rights Of Diannexin From Pharmaceutical Product
    • Astellas Pharma Acquires AMEVIVE Rights And Assets From Biogen Idec
    • Astellas Pharma Acquires Research Facility From Dynogen Dynogen Pharmaceuticals
    • EpiTherapeutics Secures An Additional $1.69 Million In Seed Financing
    • PhaseBio Pharmaceuticals Secures $15 Million In The Second Tranche Of Series B Financing Round
    • EpiTherapeutics Secures An Additional $1.37 Million In Seed Financing
    • Prolysis Secures $10 Million In Venture Financing
    • Cell Signaling Technology Enters Into Co-Marketing Agreement With Astellas Pharma
    • Maruho Enters Into Co-Marketing Agreement With Astellas
    • Astellas Pharma Enters Into Drug Discovery Collaboration With NITE
    • Astellas Pharma Enters Into An Agreement With Sanofi-Aventis
    • Astellas Pharma Enters Into Co-Development Agreement With UMN Pharma
    • Astellas Pharma Enters Into Co-Marketing Agreement With Bayer Schering Pharma
    • Astellas Pharma Extends Co-Promotion Agreement With Nippon Boehringer Ingelheim
    • Astellas Pharma Enters Into Co-Promotion Agreement With Sam Chun Dang
    • OM PHARMA Enters Into Co-Marketing Agreement With Astellas Pharma
    • Ambit Biosciences Enters Into Co-Development Agreement With Astellas Pharma
    • Medivation Enters Into Co-Development Agreement With Astellas Pharma
    • Simcere Pharmaceutical Enters Into Co-Development And Marketing Agreement With OSI Pharmaceuticals
    • Maxygen Forms Joint Venture With Astellas Pharma
    • Pfizer Enter Into Co-Promotion Agreement With Astellas Pharma
    • Astellas Pharma Enters Into Co-Promotion Agreement With AstraZeneca
    • Astellas Pharma Enters Into Co-Marketing Agreement With Zogenix
    • REGiMMUNE Enters Into Co-Development Agreement With Astellas Pharma
    • OSI Pharmaceuticals Expands Research Collaboration With AVEO Pharmaceuticals
    • Dako Denmark Enters Into An Agreement With OSI Pharmaceuticals
    • Astellas Pharma Enters Into Agreement With Maxygen
    • Astellas Pharma Enters Into Collaboration Agreement With CoMentis
    • BioTrove Enters Co-Marketing Agreement With OSI Pharmaceuticals
    • Proteros Expands Agreement With OSI Pharmaceuticals
    • Zeria Pharmaceutical Enters Into Agreement With Astellas Pharma
    • Abbott Laboratories Enters Into Agreement With Genentech, OSI And Roche
    • Effector Cell Institute Enters Into Co-Development Agreement With Astellas Pharma
    • OSI Pharmaceutical Enters Into Research Agreement With AVEO Pharmaceutical
    • Astellas Pharma Enters Into Co-Development Agreement With Kyoto University
    • Cardiome Pharma Amends Its Co-Development Agreement With Astellas US
    • AtheroGenics Extends Its Agreement With Astellas Pharma
    • Astellas Pharma Enters Into Co-Promotion Agreement With Sanofi-Aventis
    • Astellas Pharma Enters Into Collaboration Agreement With Chugai Pharmaceutical And National Institute of Technology and Evaluation
    • Portola Pharmaceuticals Enters Into Co-Development Agreement With Astellas Pharma
    • Metabolex Extends Research Agreement With Astellas Pharma
    • Aestus Therapeutics Enters Into Licensing Agreement With Astellas Pharma
    • Hikma Pharmaceuticals Enters Into Licensing Agreement With Astellas Pharma
    • Oncolys BioPharma Enters Into Licensing Agreement With Astellas Pharma
    • Astellas Pharma Extends Collaboration With MorphoSys
    • OSI Pharmaceuticals Enters Into A Licensing Agreement With Ophthotech
    • SymBio Pharmaceuticals Enters Into Licensing Agreement With Astellas Pharma
    • MorphoSys Enters Into Licensing Agreement With Astellas Pharma
    • Ingenuity Systems Enters Into Licensing Agreement With Astellas Pharma
    • Mundipharma Enters Into License Agreement With Astellas Deutschland
    • Astellas Pharma Enters Into Licensing Agreement With FibroGen
    • Astellas Pharma Enters Into Licensing Agreement With Ilypsa
    • SymBio Pharmaceuticals Enters Into Licensing Agreement With Astellas Pharma
    • Apoxis Enters Into Licensing Agreement With Astellas Pharma
    • Astellas Pharma Enters Into Licensing Agreement With AVEO Pharmaceuticals For Tivozanib
    • Optimer Pharmaceuticals Enters Into Licensing Agreement With Astellas Pharma Europe For Fidaxomicin
    • Astellas Pharma Europe Expands Its Licensing Agreement With TOLMAR For Eligard
    • PanOptica Enters Into Licensing Agreement With OSI Pharmaceuticals
    • Astellas Pharma Extends Licensing Agreement With AstraZeneca
    • OSI Pharmaceuticals Enters Into Licensing Agreement With AVEO Pharmaceuticals
    • Astellas Pharma Enters Into Licensing Agreement With ASKA Pharmaceutical For AKP-002
    • Astellas Pharma Extends Licensing Agreement With Regeneron Pharmaceuticals
    • Teijin Pharma Enters Into An Agreement With Astellas Pharma
    • Basilea Pharmaceutica Enters Into Licensing, Co-Development And Co-Promotion Agreement with Astellas Pharma
    • Ironwood Pharmaceuticals Enters Into Licensing Agreement With Astellas Pharma
    • NeurogesX Enters Into Licensing Agreement With Astellas Pharma Europe
    • Teijin Pharma Enters Into Licensing Agreement With Astellas Pharma Taiwan
    • Millipore Enters Into Licensing Agreement With Astellas
    • MorphoSys Enters Into Licensing Agreement With Astellas
    • GlaxoSmithKline Pharmaceuticals Enters Into Licensing Agreement With Astellas Pharma
    • OSI Pharmaceuticals Enters Into Licensing Agreement For TGF ß3
    • OncoVista Innovative Therapies Enters Into Licensing Agreement With OSI Pharmaceuticals
    • OSI Pharmaceuticals Amends Licensing Agreement With Pfizer
    • Astellas Pharma Enters Into Licensing Agreement With Regeneron Pharmaceuticals
    • Astellas Enters Into License Agreement With Kirin Brewery Company
    • Theravance Extends Licensing Agreement With Astellas
    • CV Therapeutics Amends Licensing Agreement With Astellas US
    • Sanofi-Aventis Enters Into Licensing Agreement With Astellas Pharma
    • Astellas Pharma Enters Into Licensing Agreement With Toyama Chemical
    • Astellas Pharma Enters Into Licensing Agreement With Immuno-Bioogical Laboratories
    • Ferring Pharmaceuticals Enters Into Licensing Agreement With Astellas Pharma
    • PR Pharmaceuticals Enters Into Licensing Agreement With OSI Pharmaceuticals
    • Astellas Pharma Enters Into Licensing Agreement With XenoPort
    • Astellas Pharma Enters Into Licensing Agreement With Theravance
    • OSI Pharmaceuticals Enters Into Licensing Agreement With Merck
    • Fujisawa Pharmaceutical Enters Into Licensing Agreement With Carlsson Research
    • Cytori Therapeutics Announces Private Placement Of $10 Million
    • Silence Therapeutics Completes Private Placement Of $24 Million
    • AVEO Pharmaceuticals Completes Private Placement Of $15 Million
    • AVEO Pharmaceuticals Completes Private Placement Of $5.5 Million
    • Astellas Pharma Sells Hoshienu Pharma To Choseido Pharmaceutical
    • Daiichi Sankyo Acquires Zepharma From Astellas Pharma
    • Biota Holdings Acquires Antibacterial Assets From Prolysis
    • APP Pharmaceuticals Acquires Manufacturing Plant From Astellas Phama
    • Temmler Pharma Acquires Three European Plants From Astellas Pharma
    • QLT Acquires Full Rights To Aczone From Astellas
    • OSI Pharmaceuticals Completes Private Placement Of Notes For $200 Million
    • OSI Pharmaceuticals Completes Senior Subordinated Notes Offering For $115 Million
    • Astellas Pharma To Acquire 83.3% Equity Interest In Perseid Therapeutics From Maxygen
    • Astellas Pharma Acquires OSI Pharmaceuticals
    • Astellas Acquires Agensys
    • Daiichi Sankyo Acquires Zepharma From Astellas Pharma
    • OSI Pharmaceuticals Acquires Eyetech Pharmaceuticals
    • OSI Pharmaceuticals Acquires Remaining Stake In Prosidion
    • Astellas Pharma Inc., Key Employees
    • Astellas Pharma Inc., Other Locations
    • Astellas Pharma Inc., Subsidiaries 170
  • List of Figures
    • Astellas Pharma Inc., Pharmaceuticals & Healthcare, Deals by Type, 2005 to YTD 2011
    • Astellas Pharma Inc., Pharmaceuticals & Healthcare, Licensing Deals by Year, 2005 to YTD 2011
    • Astellas Pharma Inc., Pharmaceuticals & Healthcare, Licensing Deals by Phase, 2005 to YTD 2011
    • Astellas Pharma Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
    • Astellas Pharma Inc., Pharmaceuticals & Healthcare, Deals by Type, 2005 to YTD 2011
    • Astellas Pharma Inc., Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2011
    • Astellas Pharma Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2005 to YTD 2011
    • Astellas Pharma Inc., Pharmaceuticals & Healthcare, Medical Devices Deals, 2005 to YTD 2011
+44 20 8816 8548

Ask a question about Astellas Pharma Inc. (4503) - Pharmaceuticals & Healthcare

Enter the characters you see in the picture below
Captcha